Mesoblast share price rips 12% on financial and operational updates

Mesoblast has set a price for its recently-approved flagship drug, which will go to market over the next few weeks.

| More on:
Doctor doing a telemedicine using laptop at a medical clinic

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Mesoblast Ltd (ASX: MSB) share price leapt 11.8% to $2.75 in early trading on Thursday after two announcements from the ASX biotech.

Mesoblast released its 1H FY25 results and announced that pricing had been set for its recently approved flagship drug, remestemcel-L, or Ryoncil, in the United States.

The drug will be made available to US clinics for ordering this quarter.

The Mesoblast share price opened at $2.69, up from $2.46 at yesterday's close. The ASX biotech share is currently trading for $2.67, up 8.33%.

Let's check out the 1H FY25 report.

Mesoblast share price surges on half-yearly results

Here are the highlights of the report:

  • Total revenue of US$3.2 million, down from $3.4 million in 1H FY24
  • Loss after tax of US$47.9 million compared to US$32.5 million for H1 FY24
  • Net Cash Outflow of US$20.7 million, down from US$26.6 million in H1 FY24
  • Cash balance of US$38 million and pro-forma cash of approximately US$200 million

What else happened in 1H FY25?

The biggest event during the half was the approval of Ryoncil to treat the devastating steroid-refractory acute graft-versus-host disease (SR-aGvHD) in children aged two years and older.

The Mesoblast share price skyrocketed by almost 70% between 19 December and 2 January after the company announced approval from the United States Food and Drug Administration (FDA).

Mesoblast shares hit a four-year high of $3.37 per share on 2 January.

SR-aGvHD is a life-threatening condition with a high mortality rate.

Approximately 10,000 patients, including 1,500 children, undergo an allogeneic bone marrow transplant every year in the US.

Approximately one in two patients develop aGvHD, and almost half of them do not respond to the current first-line treatment of steroids.

Mesoblast is now collaborating with the Blood and Marrow Transplant Clinical Trials Network (BMT CTN) in the US to conduct a pivotal trial of Ryoncil for adult patients with SR-aGvHD.

Created with Highcharts 11.4.3Mesoblast PriceZoom1M3M6MYTD1Y5Y10YALLwww.fool.com.au

What did Mesoblast management say?

Dr Silviu Itescu, Chief Executive of Mesoblast, said:

Our FDA approved product Ryoncil will be available in the coming weeks to the children with SRaGvHD in need of life-saving therapy.

The treatment has delivered long-term survival outcomes in these very high-risk patients and we are pleased with the benefits and value that this treatment brings to patients and their healthcare providers at specialized transplant centers across the U.S..

What's next for Mesoblast?

Mesoblast said Ryoncil would become available to clinics over the next few weeks.

The company said the wholesale acquisition cost (WAC) of Ryoncil had been calculated and set at US$194,000 per intravenous infusion.

Ryoncil will be distributed to US treatment centers by cryogenic services provider, Cencora.

In other news, Mesoblast has conducted a pilot study to see whether Ryoncil may be an effective treatment for inflammatory bowel disease, including Crohn's disease.

The study "demonstrated positive outcomes" in adult patients and added to existing Mesoblast data showing Ryoncil can induce early remission in Crohn's disease.

Mesoblast intends to meet with the FDA to discuss another drug, Revascor, to treat chronic heart failure. The FDA has already indicated its support for an accelerated approval pathway.

The company is also enrolling US participants in a confirmatory phase 3 trial of rexlemestrocel-L, which treats chronic lower back pain.

The FDA has approved the design of the trial.

Mesoblast share price snapshot

The Mesoblast share price has risen 768% over the past 12 months.

Wondering where you should invest $1,000 right now?

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for over ten years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

Scott just revealed what he believes could be the 'five best ASX stocks' for investors to buy right now. We believe these stocks are trading at attractive prices and Scott thinks they could be great buys right now...

See The 5 Stocks *Returns as of 30 April 2025

Motley Fool contributor Bronwyn Allen has positions in Mesoblast. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.
Healthcare Shares

Brokers tip 4 ASX 200 healthcare shares to buy now

Healthcare is a defensive sector that can provide useful cover for investors when the market is volatile.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

How Trump's tariffs have created 'upside potential' for CSL shares

A leading expert says CSL shares are now looking ‘cheap’.

Read more »

Shot of a young scientist looking stressed out while working on a computer in a lab.
Healthcare Shares

Telix shares crash 8% on US FDA blow

This high-flying stock has been hit with some bad news.

Read more »

A man wakes up happy with a smile on his face and arms outstretched.
Healthcare Shares

ResMed shares jump 8% on strong Q3 update

It was yet another strong quarter from this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Guess which ASX All Ords stock is up 10% on big news

This high-flying stock just can't stop rising. What's going on?

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

Telix shares rocket 15% on stellar Q1 sales update

Let's see how the company performed during the three months.

Read more »

Portrait, confidence and team of doctors in the hospital standing after a consultation or surgery. Success, healthcare and group of professional medical workers in collaboration at a medicare clinic.
Healthcare Shares

Macquarie's top 3 ASX stock picks in the healthcare sector

Top broker has revealed 3 healthcare stocks with upside. 

Read more »

Two lab workers fist pump each other.
Healthcare Shares

3 of the best ASX 200 healthcare shares to bring your portfolio to life

These shares could be just what the investment doctor ordered according to analysts.

Read more »